Skip to main content

Thank you for visiting nature.com. You are using a browser version with limited support for CSS. To obtain the best experience, we recommend you use a more up to date browser (or turn off compatibility mode in Internet Explorer). In the meantime, to ensure continued support, we are displaying the site without styles and JavaScript.

Comparative assessment of outcomes and adverse effects using two different intramuscular testosterone therapy regimens: 100 mg IM weekly or 200 mg IM biweekly

Abstract

This study aimed to compare the change in levels of several laboratory values and the development of adverse events using two commonly used intramuscular testosterone therapy regimens. Men were included if they were 18 years or older and received one of the following testosterone therapy regimens: 100 mg intramuscular once weekly or 200 mg intramuscular once every other week. Primary outcomes were relative changes in total testosterone, free testosterone, estradiol, prostate-specific antigen, and hematocrit at 6 months after initiation of testosterone therapy. Secondary outcomes were any significant rises in estradiol, hematocrit, prostate-specific antigen, and any other treatment-related adverse events requiring cessation of testosterone therapy. A total of 263 men were enrolled. In a subanalysis of men who had a baseline hematocrit below 54% before intramuscular testosterone therapy initiation, we found the following: men who received 100 mg weekly injections were significantly less likely to have hematocrit levels rising above 54% (1/102 (1%) vs. 4/51 (8%); p = 0.023). No significant differences were recorded in the increase in total testosterone, free testosterone, prostate-specific antigen, and estradiol levels between both groups. A higher average serum testosterone over the dosing interval seen with the 200 mg regimen appears to be associated with a higher risk of erythrocytosis.

Access options

Rent or Buy article

Get time limited or full article access on ReadCube.

from$8.99

All prices are NET prices.

Fig. 1

References

  1. 1.

    Gooren LJ, Bunck MC. Androgen replacement therapy: present and future. Drugs. 2004;64:1861–91. https://doi.org/10.2165/00003495-200464170-00002

    CAS  Article  PubMed  Google Scholar 

  2. 2.

    Kaufman JM, Vermeulen A. The decline of androgen levels in elderly men and its clinical and therapeutic implications. Endocr Rev. 2005;26:833–76. https://doi.org/10.1210/er.2004-0013.

    CAS  Article  PubMed  Google Scholar 

  3. 3.

    Zarotsky V, Huang M-Y, Carman W, Morgentaler A, Singhal PK, Coffin D, et al. Systematic literature review of the epidemiology of nongenetic forms of hypogonadism in adult males. J Horm. 2014;2014:1–17.

    Article  Google Scholar 

  4. 4.

    Nieschlag E. Testosterone treatment comes of age: new options for hypogonadal men. Clin Endocrinol. 2006;65:275–81. https://doi.org/10.1111/j.1365-2265.2006.02618.x

    CAS  Article  Google Scholar 

  5. 5.

    Minnemann T, Schubert M, Freude S, Hübler D, Gouni-Berthold I, Schumann C, et al. Comparison of a new long-acting testosterone undecanoate formulation vs testosterone enanthate for intramuscular androgen therapy in male hypogonadism. J Endocrinol Investig. 2008;31:718–23. https://doi.org/10.1007/BF03346421

    CAS  Article  Google Scholar 

  6. 6.

    Hudson’s guide: testosterone types and delivery. Hudson’s FTM Resource Guide. http://www.ftmguide.org/ttypes.html#bib.

  7. 7.

    Kang D-Y, Li H-J. The effect of testosterone replacement therapy on prostate-specific antigen (PSA) levels in men being treated for hypogonadism: a systematic review and meta-analysis: a systematic review and meta-analysis. Medicine. 2015;94:e410.

    CAS  Article  Google Scholar 

  8. 8.

    Jones SD Jr, Dukovac T, Sangkum P, Yafi FA, Hellstrom WJG. Erythrocytosis and polycythemia secondary to testosterone replacement therapy in the aging male. Sex Med Rev. 2015;3:101–12.

    Article  Google Scholar 

  9. 9.

    Ponce OJ, Spencer-Bonilla G, Alvarez-Villalobos N, Serrano V, Singh-Ospina N, Rodriguez-Gutierrez R, et al. The efficacy and adverse events of testosterone replacement therapy in hypogonadal men: a systematic review and meta-analysis of randomized, placebo-controlled trials. J Clin Endocrinol Metab. 2018. https://doi.org/10.1210/jc.2018-00404.

  10. 10.

    Ohlander SJ, Varghese B, Pastuszak AW. Erythrocytosis following testosterone therapy. Sex Med Rev. 2018;6:77–85. https://doi.org/10.1016/j.sxmr.2017.04.001

    Article  PubMed  Google Scholar 

  11. 11.

    Griesshammer M, Kiladjian J-J, Besses C. Thromboembolic events in polycythemia vera. Ann Hematol. 2019;98:1071–82.

    Article  Google Scholar 

  12. 12.

    Cuthbert D, Stein BL. Polycythemia vera-associated complications: pathogenesis, clinical manifestations, and effects on outcomes. J Blood Med. 2019;10:359–71.

    CAS  Article  Google Scholar 

  13. 13.

    Krauss DJ, Taub HA, Lantinga LJ, Dunsky MH, Kelly CM. Risks of blood volume changes in hypogonadal men treated with testosterone enanthate for erectile impotence. J Urol. 1991;146:1566–70. https://doi.org/10.1016/s0022-5347(17)38168-5

    CAS  Article  PubMed  Google Scholar 

  14. 14.

    Corona G, Maseroli E, Rastrelli G, Isidori AM, Sforza A, Mannucci E, et al. Cardiovascular risk associated with testosterone-boosting medications: a systematic review and meta-analysis. Expert Opin Drug Saf. 2014;13:1327–51. https://doi.org/10.1517/14740338.2014.950653

    CAS  Article  PubMed  Google Scholar 

  15. 15.

    Nelson WG. Commentary on Huggins and Hodges: “studies on prostatic cancer. Cancer Res. 2016;76:186–7.

    CAS  Article  Google Scholar 

  16. 16.

    Khera M, Crawford D, Morales A, Salonia A, Morgentaler A. A new era of testosterone and prostate cancer: from physiology to clinical implications. Eur Urol. 2014;65:115–23. https://doi.org/10.1016/j.eururo.2013.08.015

    CAS  Article  PubMed  Google Scholar 

  17. 17.

    Boyle P, Koechlin A, Bota M, d’Onofrio A, Zaridze DG, Perrin P, et al. Endogenous and exogenous testosterone and the risk of prostate cancer and increased prostate-specific antigen (PSA) level: a meta-analysis. BJU Int. 2016;118:731–41. https://doi.org/10.1111/bju.13417

    CAS  Article  PubMed  Google Scholar 

  18. 18.

    Eckman A, Dobs A. Drug-induced gynecomastia. Expert Opin Drug Saf. 2008;7:691–702. https://doi.org/10.1517/14740330802442382

    CAS  Article  PubMed  Google Scholar 

  19. 19.

    Tan RS, Cook KR, Reilly WG. High estrogen in men after injectable testosterone therapy: the low T experience. Am J Mens Health. 2015;9:229–34. https://doi.org/10.1177/1557988314539000

    Article  PubMed  Google Scholar 

Download references

Author information

Affiliations

Authors

Corresponding author

Correspondence to Faysal A. Yafi.

Ethics declarations

Conflict of interest

The authors declare no competing interests.

Additional information

Publisher’s note Springer Nature remains neutral with regard to jurisdictional claims in published maps and institutional affiliations.

Rights and permissions

Reprints and Permissions

About this article

Verify currency and authenticity via CrossMark

Cite this article

El-Khatib, F.M., Huynh, L.M., Kopelevich, A. et al. Comparative assessment of outcomes and adverse effects using two different intramuscular testosterone therapy regimens: 100 mg IM weekly or 200 mg IM biweekly. Int J Impot Res (2021). https://doi.org/10.1038/s41443-021-00449-0

Download citation

Search

Quick links